Clinical Trials List
2019-01-01 - 2026-04-30
Phase III
Terminated5
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- HSIN-AN HOU Division of Hematology & Oncology
- CHENG-HONG TSAI Division of Hematology & Oncology
- 田豐銘 Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- 林建廷 Division of Hematology & Oncology
- Shang-Yi Huang Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- - - 未分科
- Chien-Chin Lin Division of Others -
- Jih-Luh Tang Division of Hematology & Oncology
- Wen-Chien Chou Division of Others -
The Actual Total Number of Participants Enrolled
0 Completed
Audit
None
Co-Principal Investigator
- Tzeon-jye Chiou Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- Po-Shen Ko Division of Hematology & Oncology
- Jyh-Pyng Gau Division of Hematology & Oncology
- Sheng-Hsuan Chien Division of Hematology & Oncology
- Chia-Jen Liu 無
- Hao-Yuan Wang 無
- Liang-Tsai Hsiao Division of Hematology & Oncology
- Yao-Chung Liu 無
The Actual Total Number of Participants Enrolled
0 Completed
The Actual Total Number of Participants Enrolled
0 Completed
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
- Tsung -Chih Chen Division of Hematology & Oncology
- HSIN-CHEN LIN Division of Hematology & Oncology
- 韓紹民 Division of Hematology & Oncology
- YU-HSUAN SHIH Division of Hematology & Oncology
- CHENG-HSIEN LIN Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
291 participants
